Preclinical · Oral small molecules · Neuro-immune disease
We let the biology choose the disease
Azalla is a small, science-led development company advancing two oral small molecules from a single proprietary chemical class into two serious neuro-immune diseases. We characterized the chemistry first, read what it actually did in a living immune system, and let that evidence select the indications — rather than starting from a disease and hoping the molecule would cooperate.
How we work
Following the science, not a predetermined mission
Plenty of companies begin with a disease they want to own and search for something to put against it. We took the opposite route, and it changed which diseases we are in, which asset leads, and how much it costs to run both.
The data nominated the indications
Both compounds were first characterized in a general autoimmune model rather than a disease-specific one. The mechanistic and cytokine signature each molecule produced is what pointed one at dermatomyositis and the other at multiple sclerosis. The indication came second, on purpose.
Nimble where it counts
Strategy, chemistry and study design stay in house. Execution runs through named specialist groups who already have the assay, the model or the method validated. Direction can change in a week rather than a budget cycle, and capacity scales with the program instead of the payroll.
Capital efficiency is engineered in
One chemical class, one synthetic route, one formulation platform and one manufacturing base serve both candidates. The orphan-eligible asset leads because that path is shorter. Every line of spend has to buy a data point that changes a decision.
Pipeline
Two candidates, deliberately sequenced
Both compounds have completed in vivo proof of concept and are ready to enter IND-enabling development. J-041 leads because the data pointed to an orphan indication with a shorter regulatory path. J-019 follows on the same chemistry, formulation and manufacturing platform rather than starting from scratch.
An oral, CB2-selective full agonist. In vivo efficacy is complete and the compound is IND-enabling ready.
- Mechanism
- Full CB2 agonist, selective over CB1
- In vivo
- Interferon-pathway cytokines significantly reduced
- Next gate
- Orphan designation filing, then IND
An oral CB2 agonist with confirmed PPARγ activity — a dual mechanism addressing both the immune attack and nerve tissue protection.
- Mechanism
- CB2 agonist with confirmed PPARγ activity
- In vivo
- Disease severity significantly reduced at both dose levels
- Next gate
- CNS target engagement study
Evidence
We designed the hard study, not the flattering one
Both compounds were tested in a standard, well-characterized autoimmune inflammation model, dosed once daily over a multi-week course and scored blind by an independent contract research organization. We set a potent corticosteroid as the active comparator rather than testing against vehicle alone — a materially harder comparison, and the only one that tells you anything useful.
Held its position against a steroid
At its efficacious dose, J-041 was statistically indistinguishable from the corticosteroid comparator at every measurement timepoint across the study — the only test arm to hold that position for the full duration.
Function, not just appearance
A functional endpoint measured independently of disease scoring improved significantly against vehicle for both compounds, and neither was separable from the steroid comparator on that measure.
Mechanism read in tissue and blood
A broad terminal cytokine panel showed dose-ordered reductions in TNF-α, IL-15, CXCL10 and CXCL9. Histopathology showed a significant dose-response in both limbs scored. This panel is what selected each indication.
Study designs, dose levels, effect sizes and statistical detail are held as confidential data and are shared with partners and prospective investors under a confidentiality agreement.
Areas of focus
Two diseases where an oral option does not yet exist
Neither indication was chosen for its size. Each was chosen because the mechanistic signature our compounds produced maps onto the biology of that disease, and because the people living with it have very few options that can be taken as a tablet.
Dermatomyositis — lead program
A rare autoimmune disease of skin and muscle
- US prevalence is estimated at 13 to 21 per 100,000 — roughly 34,000 to 55,000 people, with about 38,500 diagnosed cases in the United States.
- One therapy is approved for adult dermatomyositis: an intravenous immunoglobulin infusion. Everything else in routine use is off-label steroids and broad immunosuppression.
- No oral small molecule is approved, and the indication qualifies for FDA orphan drug designation.
- The disease is driven in part by an interferon signature — the same pathway our lead compound acts on most strongly.
Multiple sclerosis — second program
A chronic neuro-immune disease with a gap in progression
- Approximately 914,000 people in the United States and 2.8 to 2.9 million worldwide live with MS.
- Most people with MS eventually progress, and the therapies that exist address relapses far better than they address progression.
- Orally available mechanisms that act on both inflammation and neuroprotection are what the field has been trying to build.
- J-019 pairs CB2 agonism with confirmed PPARγ activity in a single oral molecule, which is why this indication followed the data.
Source: Arthritis Care & Research, FDA, PLOS ONE, National MS Society, Multiple Sclerosis International Federation, Practical Neurology.
J-041 and J-019 are investigational and have not been tested in humans. Nothing on this page is a claim of clinical benefit.
Talk to us about the programs
Scientific, partnering, clinical, media and corporate inquiries all come through one form and are read by the people running the program.